![]() Latest Analyst Research & Price Targets for Surmodics Inc (SRDX-Q). We can’t assure its accuracy, please only use it as an initial alert system. Next Qtr 12/2022 Fiscal Yr 09/2022 Fiscal Yr 09/2023 Average Estimate -0.36 : 1.06 -1.08 : 0.38. Our cash burn information is purely based on mathematical estimates from a company’s quarterly filing. This reflects a positive earnings surprise of 31.25. As a rule of thumb, if the cash in a small biotech firm can only last less than 12 months based on its cash burning rate, it may do secondary offering any time. For their last quarter, Surmodics (SRDX) reported earnings of -0.22 per share, beating the Zacks Consensus Estimate of -0.32 per share. So, you must know this and check cash situation for all the stocks in your portfolio. Going public and raising money again and again through secondary offering is an inherent guarantee in this industry. Earnings were 4.24 million, an increase of 277.29. No venture capital investors can bear such risk alone. IPO Date CEO Gary Maharaj Employees 389 Stock Exchange NASDAQ Ticker Symbol SRDX Full Company Profile Financial Performance In 2021, SurModics's revenue was 105.14 million, an increase of 10.83 compared to the previous year's 94.86 million. A typical drug development, from pre-screening until passing Phase III clinical trials and FDA approval, may well cost a few hundreds of millions of dollars or even more than one billion dollars in some cases. 432 - 468 with code Save 589 The 40,000 square feet outlet offers discounted prices on discontinued, or as-is furniture. a fully franked dividend of 1.35 cents per share for the June quarter. No new target decision date has been provided. ![]() To date, positional cues required for epidermal/mesophyll cell fate. Unlike an IT start-up, which could start in your garage like google and become a huge player later, small biotech startups require intensive capital investments before they can really produce a product and start to make money. (NASDAQ:SRDX), a leading provider of medical. The North Chicago, Illinois pharma achieved second quarter revenues of 14.6 billion, a 6.1 operational. Expression of ATML1-SRDX, which is supposed to downregulate target genes of ATML1. The reported (0.22) earnings per share for the quarter, beating analysts consensus. It is crucial to check cash and the cash burning situation on small biotech firms. Surmodics last posted its quarterly earnings data on April 27th, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |